YF-VAX Related Published Studies
Well-designed clinical trials related to YF-VAX (Yellow Fever Vaccine)
Intradermally administered yellow fever vaccine at reduced dose induces a protective immune response: a randomized controlled non-inferiority trial. [2008.04.23]
Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: Phase I clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes. [2006.03]
Yellow fever 17D vaccine safety and immunogenicity in the elderly. [2005.09]
Reactogenicity of yellow fever vaccines in a randomized, placebo-controlled trial. [2005.06]
Immunogenicity and safety of BERNA-YF compared with two other 17D yellow fever vaccines in a phase 3 clinical trial. [2005.03]
Randomized, double-blind, phase III, pivotal field trial of the comparative immunogenicity, safety, and tolerability of two yellow fever 17D vaccines (Arilvax and YF-VAX) in healthy infants and children in Peru. [2005.02]
Immunogenicity of WHO-17D and Brazilian 17DD yellow fever vaccines: a randomized trial. [2004.10]
Comparative safety and immunogenicity of two yellow fever 17D vaccines (ARILVAX and YF-VAX) in a phase III multicenter, double-blind clinical trial. [2002.05]
An open randomized study of inactivated hepatitis A vaccine administered concomitantly with typhoid fever and yellow fever vaccines. [2002.03]
Antibody response to 17D yellow fever vaccine in Ghanaian infants. [2001]
Comparison of the immunogenicity and safety of two 17D yellow fever vaccines. [1999.06]
Recent immunization against measles does not interfere with the sero-response to yellow fever vaccine. [1999.03.05]
Safety and immunogenicity of live oral cholera and typhoid vaccines administered alone or in combination with antimalarial drugs, oral polio vaccine, or yellow fever vaccine. [1997.04]
Interference assessment of yellow fever vaccine with the immune response to a single-dose inactivated hepatitis A vaccine (1440 EL.U.). A controlled study in adults. [1996.08]
[Simultaneous vaccination against hepatitis A and yellow fever] [1993]
The effect of chloroquine prophylaxis on yellow fever vaccine antibody response: comparison of plaque reduction neutralization test and enzyme-linked immunosorbent assay. [1991.01]
Safety and efficacy of yellow fever vaccine in children less thanone-year-old. [1990.07]
Study of combined vaccination against yellow fever and measles in infants from six to nine months. [1989.01]
Well-designed clinical trials possibly related to YF-VAX (Yellow Fever Vaccine)
A live, attenuated recombinant West Nile virus vaccine. [2006.04.25]
Exercise-induced serum enzyme elevations confounding the evaluation of investigational drug toxicity. Report of two cases in a vaccine trial. [2005.01]
Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigen. [2003.10.15]
Chlamydia antibody response in healthy volunteers immunized with nonchlamydial antigens: a randomized, double-blind, placebo-controlled study. [2003.03.01]
Clinical proof of principle for ChimeriVax: recombinant live, attenuated vaccines against flavivirus infections. [2002.01.15]
Other research related to YF-VAX (Yellow Fever Vaccine)
Men with low vitamin A stores respond adequately to primary yellow fever and secondary tetanus toxoid vaccination. [2008.11]
Comprehensive analysis of T cell epitope discovery strategies using 17DD yellow fever virus structural proteins and BALB/c (H2d) mice model. [2008.08.15]
Yellow fever vaccines and international travelers. [2008.07]
Immune response during adverse events after 17D-derived yellow fever vaccination in Europe. [2008.06.01]
Pressure-inactivated yellow fever 17DD virus: implications for vaccine development. [2008.06]
Yellow fever-associated viscerotropic disease in Barcelona, Spain. [2008.05]
Detection of Th1/Th2 cytokine signatures in yellow fever 17DD first-time vaccinees through ELISpot assay. [2008.05]
Treatment of yellow fever. [2008.04]
Recombinant chimeric virus with wild-type dengue 4 virus premembrane and envelope and virulent yellow fever virus Asibi backbone sequences is dramatically attenuated in nonhuman primates. [2008.03.01]
Evaluation of two yellow fever vaccines for routine immunization programs in Argentina. [2008.03]
Innate immunity phenotypic features point toward simultaneous raise of activation and modulation events following 17DD live attenuated yellow fever first-time vaccination. [2008.02.26]
Yellow fever control in Cameroon: where are we now and where are we going? [2008.02.08]
Fatal multiorgan failure due to yellow fever vaccine-associated viscerotropic disease. [2007.12.05]
Yellow fever and Max Theiler: the only Nobel Prize for a virus vaccine. [2007.11.26]
Yellow fever 17-D vaccine is neurotropic and produces encephalitis in immunosuppressed hamsters. [2007.11]
Acute viscerotropic disease following vaccination against yellow fever. [2007.10]
Early exposure to yellow fever vaccine during pregnancy. [2007.07]
Activity of T-1106 in a hamster model of yellow Fever virus infection. [2007.06]
[Immunization against yellow fever] [2007.05.16]
Neurological adverse events temporally associated to mass vaccination against yellow fever in Juiz de Fora, Brazil, 1999-2005. [2007.04.20]
17D yellow fever vaccines: new insights. A report of a workshop held during the World Congress on medicine and health in the tropics, Marseille, France, Monday 12 September 2005. [2007.04.12]
Activation/modulation of adaptive immunity emerges simultaneously after 17DD yellow fever first-time vaccination: is this the key to prevent severe adverse reactions following immunization? [2007.04]
Yellow fever: epidemiology and prevention. [2007.03.15]
Neurologic disease associated with 17D-204 yellow fever vaccination: a report of 15 cases. [2007.02.26]
Restricted replication and lysosomal trafficking of yellow fever 17D vaccine virus in human dendritic cells. [2007.01]
Innate immune responses in human dendritic cells upon infection by chimeric yellow-fever dengue vaccine serotypes 1-4. [2007.01]
Herpes zoster after yellow fever vaccination. [2007.01]
Multiple evanescent white dot syndrome following simultaneous hepatitis-A and yellow fever vaccination. [2006.10]
Epizootics of yellow fever in Venezuela (2004-2005): an emerging zoonotic disease. [2006.10]
Yellow fever vaccine-associated viscerotropic disease (YEL-AVD) and corticosteroid therapy: eleven United States cases, 1996-2004. [2006.08]
Yellow fever vaccine-associated viscerotropic disease and death in Spain. [2006.06]
Neutralizing antibody response to booster vaccination with the 17d yellow fever vaccine. [2006.04.05]
Characterization of a viscerotropic yellow fever vaccine variant from a patient in Brazil. [2006.04.05]
Late vaccination against yellow fever of travelers visiting endemic countries. [2006.03]
The effects of yellow fever immunization (17DD) inadvertently used in early pregnancy during a mass campaign in Brazil. [2006.02.27]
A recombinant Yellow Fever 17D vaccine expressing Lassa virus glycoproteins. [2006.02.20]
Vaccination coverage survey versus administrative data in the assessment of mass yellow fever immunization in internally displaced persons--Liberia, 2004. [2006.02.06]
[Flavivirus infections: yellow fever, dengue fever and Japanese encephalitis] [2005.10.24]
New developments in flavivirus vaccines with special attention to yellow fever. [2005.10]
Yellow fever vaccine. [2005.08]
Evaluation of yellow fever vaccination centers in Canada. [2005.07]
Yellow fever vaccination: how much is enough? [2005.06.10]
West Nile virus infection and serologic response among persons previously vaccinated against yellow fever and Japanese encephalitis viruses. [2005.06]
Rare case of fatal yellow fever vaccine-associated viscerotropic disease. [2005.06]
Yellow fever vaccine: an updated assessment of advanced age as a risk factor for serious adverse events. [2005.05.09]
Yellow fever and Japanese encephalitis vaccines: indications and complications. [2005.03]
Safety of the yellow fever vaccine during the September 2001 mass vaccination campaign in Abidjan, Ivory Coast. [2004.11.25]
Risk of fatal adverse events associated with 17DD yellow fever vaccine. [2004.10]
[Yellow fever--a tropical danger] [2004.08.05]
Current status of the Arilvax; yellow fever vaccine. [2004.08]
Interindividual variation in the response by fibrinogen, C-reactive protein and interleukin-6 to yellow fever vaccination. [2004.07]
Viscerotropic and neurotropic disease following vaccination with the 17D yellow fever vaccine, ARILVAX. [2004.06.02]
Safety and efficacy of chimeric yellow Fever-dengue virus tetravalent vaccine formulations in nonhuman primates. [2004.05]
Yellow fever vaccine: a successful vaccination of an immunocompromised patient. [2004.04]
[Yellow fever] [2004]
Yellow fever: the recurring plague. [2004]
Age-related risk of adverse events following yellow fever vaccination in Australia. [2004]
Neurovirulence of yellow fever 17DD vaccine virus to rhesus monkeys. [2003.11.10]
MAC-ELISA and ELISA inhibition methods for detection of antibodies after yellow fever vaccination. [2003.06.30]
[Yellow Fever] [2003.03]
Identification and characterization of avian retroviruses in chicken embryo-derived yellow fever vaccines: investigation of transmission to vaccine recipients. [2003.01]
Pathogenesis and pathophysiology of yellow fever. [2003]
A Belgian traveler who acquired yellow fever in the Gambia. [2002.11.15]
Yellow fever vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2002. [2002.11.08]
Yellow fever vaccine safety: a reality or a myth? [2002.11.01]
[Antibody responses in Japanese volunteers after immunization with yellow fever vaccine] [2002.09]
[An epidemic risk of yellow fever in Burkina Faso despite a rapid immunisation riposte: role of a multidisciplinary investigation team] [2002.07]
Viremia and immunogenicity in nonhuman primates of a tetravalent yellow fever-dengue chimeric vaccine: genetic reconstructions, dose adjustment, and antibody responses against wild-type dengue virus isolates. [2002.06.20]
Prevention of yellow fever in persons traveling to the tropics. [2002.05.15]
Yellow fever virus 17D envelope and NS3 proteins are major targets of the antiviral T cell response in mice. [2002.04.25]
Low frequency of side effects following an incidental 25 times concentrated dose of yellow fever vaccine. [2002.03]
Fatal myeloencephalitis following yellow fever vaccination in a case with HIV infection. [2002.01]
[Detection and management of the yellow fever epidemic in the Ivory Coast, 2001] [2002]
Inadequate protection against yellow fever of children visiting endemic areas. [2001.12]
Phenotypic and molecular analyses of yellow fever 17DD vaccine viruses associated with serious adverse events in Brazil. [2001.11.25]
Advanced age a risk factor for illness temporally associated with yellow fever vaccination. [2001.11]
[Neuritis of the optic nerve after vaccinations against hepatitis A, hepatitis B and yellow fever] [2001.10]
Construction, safety, and immunogenicity in nonhuman primates of a chimeric yellow fever-dengue virus tetravalent vaccine. [2001.08]
|
